TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 4036847
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg cholesterol daily
Study: 4036847
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg cholesterol daily (healthy women)
Study: 4036847
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg cholesterol daily (healthy women)
Study: 20977087
Drug: RMK (0.25%
Approvals — FDA: no, EMA: no, PMDA: no
Description: RMK (0.25% ropivacaine, morphine 0.2 mg/mL, ketorolac 1 mg/mL)
Study: 12358160
Drug: Carbamazepine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine (400 mg) - Test formulation
Study: 12358160
Drug: Carbamazepine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine (400 mg) - Reference formulation
Study: 7488279
Drug: CAMPATH‐1H (1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAMPATH‐1H (1, 3, 10, 30, 60, and 100 mg)
Study: 2297656
Drug: 6-hour continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-hour continuous infusion of doxorubicin
Study: 2297656
Drug: Standard rapid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard rapid infusion of doxorubicin (15 to 20 minutes)
Study: 2297656
Drug: Standard rapid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard rapid infusion of doxorubicin
Study: 7348120
Drug: Pentazocine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentazocine (1 mg/kg)
Study: 7348120
Drug: No opiate
Approvals — FDA: no, EMA: no, PMDA: no
Description: No opiate antagonists
Study: 23708746
Drug: Gabapentin generic
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin generic formulations (three generic formulations)
Study: 23708746
Drug: Branded formulation
Normalized name: Eagle Brand Medicated Oil
DrugBank: Eucalyptus oil (DB11114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Branded formulation of gabapentin
Study: 21062906
Drug: Certain medications
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Certain medications
Study: 17244243
Drug: 1 unit/ml
Normalized name: vasopressin 1 unit/mL-D5% intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 unit/ml of heparin saline
Study: 17244243
Drug: 10 units/ml
Normalized name: heparin 10 units/mL injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 units/ml of heparin saline
Study: 12647460
Drug: Day hospital
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day hospital treatment for acute psychiatric patients
Study: 8605897
Drug: Ceftriaxone 1
Normalized name: ceftriaxone 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 1 g/day
Study: 2897008
Drug: Ceftriaxone 2
Normalized name: ceftriaxone 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 2 g/day
Study: 2665059
Drug: Insulin treatment
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin treatment (25 U fast-acting insulin bolus followed by continuous infusion of 1 U/kg b.w. for 1 hour)
Study: 23709323
Drug: Crushed MSN
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crushed MSN (≥60/2.4 mg)
Study: 9301462
Drug: Amifostine (910
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amifostine (910 mg/m2) before cyclophosphamide (1500 mg/m2) for two cycles
Study: 3434998
Drug: Standardized aggressive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized aggressive treatment including wide resection, adjuvant radio- or chemotherapy and management of advanced disease
Study: 3434998
Drug: Adjuvant cytostatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant cytostatic therapy in patients with colonic tumours of Dukes B and C stages
Study: 3434998
Drug: Irradiation followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Irradiation followed by attempted curative surgery in primarily inoperable rectal cancer
Study: 19329546
Drug: 300 mg/74
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg/74 mg BZP/TFMPP
Study: 19329546
Drug: 57.6 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 57.6 g (6 units) alcohol
Study: 18622632
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) 1200 mg/m(2) per day (n = 12)
Study: 18622632
Drug: Cyclosporine A
Normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine A (CsA) 4-5 mg/kg per day (n = 12)
Study: 15882244
Drug: Lansoprazole, amoxicillin
Normalized name: lansoprazole, amoxicillin and levofloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole, amoxicillin and clarithromycin (antibiotic group)
Study: 15882244
Drug: Lansoprazole and
Normalized name: Lansoprazole and naproxen only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole and identical antibiotic placebos (control group)
Study: 8843174
Drug: Parenteral fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral fish oil (FO) at 0.15 g/kg/d for 5 days
Study: 8843174
Drug: Soybean oil
Normalized name: Soybean Oil
DrugBank: Soybean oil (DB09422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soybean oil (SO) at 1.0 g/kg/d for 5 days
Study: 1509577
Drug: Foot zone
Normalized name: Na-zone
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Foot zone therapy (10 sessions of 1 hour each at intervals of one week)
Study: 1509577
Drug: Uniform clinical
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uniform clinical care without placebo foot zone therapy
Study: 6373340
Drug: Almitrine bismesylate
Normalized name: almitrine dimesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almitrine bismesylate (100 mg orally)
Study: 29789243
Drug: MenACWY-TT and
Normalized name: meningococcal conjugate quadrivalent, MenACWY-TT (MCV4)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenACWY-TT and AS04-HPV16/18 co-administered
Study: 29789243
Drug: MenACWY-TT, AS04-HPV16/18
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenACWY-TT, AS04-HPV16/18 and Tdap co-administered
Study: 29789243
Drug: Tdap and
Normalized name: metformin and ertugliflozin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tdap and AS04-HPV16/18 co-administered
Study: 18349394
Drug: Irinotecan/FU/FA combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan/FU/FA combination therapy
Study: 11498702
Drug: Cefepime (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefepime (2 g every 8 or 12 hours)
Study: 9065256
Drug: Low-dose heparin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose heparin prophylaxis (fractionated or unfractionated)
Study: 6881119
Drug: Bromocriptine 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine 15 mg/day plus cleansing enemas
Study: 6881119
Drug: Bromocriptine 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine 30 mg/day plus cleansing enemas
Study: 6881119
Drug: Neomycin 6
Normalized name: neomycin 65000 UNT/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neomycin 6 g/day plus cleansing enemas (standard therapy)
Study: 30672248
Drug: Electroacupuncture (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture (EA) treatment at Baihui (GV 20), Fengfu (GV 16), Shenting (GV 24), Taiyang (EX‐HN 5), Shangyintang (Extra 3), Dazhong (KI 14); EA applied at Taiyang (EX‐HN 5), Baihui (GV 20), Shenting (GV 24) with dilatational wave, 10 Hz/50 Hz frequency, 0.5 to 5.0 mA intensity, once every two days, three treatments per week for 12 weeks.
Study: 30672248
Drug: Donepezil hydrochloride
Normalized name: Donepezil Hydrochloride
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Donepezil hydrochloride tablets, once a day before sleep for 12 weeks.
Study: 30672248
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups evaluated at baseline, 12 weeks, and 24 weeks after treatment.
Study: 28230390
Drug: Deprexis (Internet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deprexis (Internet treatment for depression) for 8 weeks
Study: 1398561
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of diethylstilbestrol
Study: 2993946
Drug: ACTH 4‐9
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACTH 4‐9 analogue (ORG 2766), 80 mg daily during 14‐28 days
Study: 20191360
Drug: Taranabant 2-8
Normalized name: Taranabant
DrugBank: Taranabant (DB06624)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taranabant 2-8 mg
Study: 20837597
Drug: Nucleotide-supplemented formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nucleotide-supplemented formula (31 mg/L)
Study: 12380632
Drug: Glyburide/metformin 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glyburide/metformin 1.25 mg/250 mg tablets BID for HbA1c < 9%; Glyburide/metformin 2.5 mg/500 mg tablets BID for HbA1c >= 9%.
Study: 12380632
Drug: Glyburide/metformin tablets.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glyburide/metformin tablets.
Study: 1769141
Drug: Preparation A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation A: rhEPO 2000 IU in 1 ml (Cilag)
Study: 1769141
Drug: Preparation B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation B: rhEPO 2000 IU in 1 ml (Boehringer Mannheim)
Study: 1769141
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline 1 ml (placebo)
Study: 28081945
Drug: Fluocinolone Acetonide
Normalized name: Fluocinolone Acetonide
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluocinolone Acetonide (FAc) 0.2 μg/day
Study: 28081945
Drug: Fluocinolone Acetonide
Normalized name: Fluocinolone Acetonide
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluocinolone Acetonide (FAc) 0.5 μg/day
Study: 28081945
Drug: Fluocinolone Acetonide
Normalized name: Fluocinolone Acetonide
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluocinolone Acetonide (FAc) 0.2 μg/day and 0.5 μg/day
Study: 23463655
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 (all doses)
Study: 10437863
Drug: Control (placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (placebo plus conventional antihypertensive therapy)
Study: 7767512
Drug: Inhaled beclomethasone
Normalized name: beclomethasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beclomethasone dipropionate (BDP) 400 micrograms/day for 7 months
Study: 6104610
Drug: H1 antihistamine
Normalized name: Ahist Antihistamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: H1 antihistamine (chlorpheniramine)
Study: 6104610
Drug: H2 antihistamines
Normalized name: Ahist Antihistamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: H2 antihistamines
Study: 30554141
Drug: Treatment response
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment response
Study: 30741025
Drug: Shen Cao
Normalized name: Ren shen
DrugBank: Ginseng (DB01404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shen Cao granules (10 g once daily)
Study: 28937980
Drug: Probiotic mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic mixture composed of five Lactobacilli strains and two Bifidobacteria strains, administered once a day for 60 days
Study: 3307386
Drug: Monocomponent pertussis
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monocomponent pertussis toxoid vaccine (JNIH‐7)
Study: 3307386
Drug: Two-component vaccine
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-component vaccine (JNIH‐6)
Study: 30326609
Drug: Micronutrient Powders
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronutrient Powders (MNP) with low iron dose (6 mg/serving)
Study: 22606361
Drug: Low plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low plasma ferritin (<30 µg/L)
Study: 22606361
Drug: Low plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low plasma ferritin (<30 µg/L) among HIV-infected patients
Study: 22606361
Drug: High plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: High plasma ferritin (>150 µg/L for women and >200 µg/L for men)
Study: 16047554
Drug: Chunghyul‐dan 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chunghyul‐dan 1200 mg once a day for 2 weeks
Study: 12145067
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine 100 microg (IT 100 group)
Study: 12145067
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine 200 microg (IT 200 group)
Study: 12145067
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine 3 mg (Epidural group)
Study: 14586167
Drug: Naftidrofuryl (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naftidrofuryl (400 mg)
Study: 23117550
Drug: Low-dose concentration
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose concentration MSCs (20 million cells)
Study: 12872612
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination bi-layer tablet (Quadroplus)
Study: 12872612
Drug: Tablets containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets containing solely spirapril hydrochloride monohydrate (Quadropril)
Study: 12872612
Drug: Hydrochlorothiazide (produced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (produced exclusively for study medication)
Study: 11044578
Drug: Androgen receptor
Normalized name: Androgen receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen receptor mRNA expression in hippocampal tissue
Study: 8644545
Drug: Prick test
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prick test with 10% fluorescein solution
Study: 8644545
Drug: Prick test
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prick test with 1.0% fluorescein solution
Study: 8644545
Drug: Intradermal skin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal skin test with 10% fluorescein solution
Study: 8644545
Drug: Intradermal skin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal skin test with 0.1% fluorescein solution
Study: 6704973
Drug: Autologous tumor
Normalized name: DNP-Modified autologous tumor vaccine
DrugBank: DNP-Modified autologous tumor vaccine (DB17436)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous tumor cells plus Bacillus Calmette‐Guérin vaccine
Study: 22574591
Drug: Shuxuening Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shuxuening Injection (SI), 15 mL by intravenous dripping, twice daily for 14 days
Study: 22574591
Drug: Routine therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine therapies for COPD (Control)
Study: 16013622
Drug: Repeated video
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated video feedback over 3 consecutive weekly practice sessions
Study: 8959943
Drug: Deferiprone (3-6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferiprone (3-6 g daily)
Study: 29727906
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg dapagliflozin for one month (TP1)
Study: 29727906
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg saxagliptin for one month (TP2)
Study: 29727906
Drug: Dapagliflozin and
Normalized name: Dapagliflozin and metformin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin and saxagliptin combination
Study: 24710957
Drug: Rocuronium 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.6 mg·kg(‐1) with sugammadex 4.0 mg·kg(‐1)
Study: 24710957
Drug: Succinylcholine 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Succinylcholine 1.0 mg·kg(‐1)
Study: 20009394
Drug: Moxifloxacin-based triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin-based triple therapy
Study: 20009394
Drug: Clarithromycin-based triple
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin-based triple therapy
Study: 11679006
Drug: tazarotene gel
Normalized name: Tazarotene
DrugBank: Tazarotene (DB00799)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tazarotene gel 0.1%
Study: 11679006
Drug: diflorasone diacetate
Normalized name: Diflorasone Diacetate
DrugBank: Diflorasone (DB00223)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: diflorasone diacetate 0.05% ointment
Study: 11679006
Drug: diflorasone diacetate
Normalized name: Diflorasone Diacetate
DrugBank: Diflorasone (DB00223)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: diflorasone diacetate 0.05% ointment + tazarotene gel 0.1%
Study: 9490342
Drug: Neoton (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoton (4 different schemes) administered in the acute period of MI to 97 patients.
Study: 2977404
Drug: Low-dose captopril
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose captopril (6.25 mg twice daily)
Study: 2977404
Drug: High-dose captopril
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose captopril (25 mg twice daily)
Study: 24325386
Drug: Carnitine (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carnitine (1000 mg oral solution twice daily for 4 weeks)
Study: 24325386
Drug: Placebo (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (10 mL oral solution twice daily for 4 weeks)
Study: 17869987
Drug: Ethylene oxide
Normalized name: Ethylene oxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethylene oxide sterilization (E1 group - once, E2 group - twice, E3 group - three times)
Study: 15028552
Drug: Immediate 12-week
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate 12-week parent and child treatment
Study: 15028552
Drug: Delayed-treatment condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed-treatment condition (control)
Study: 11404721
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (amoxicillin, clarithromycin, pantoprazole)
Study: 11404721
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (tinidazole, clarithromycin, ranitidine bismuth citrate)
Study: 11404721
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (tinidazole, clarithromycin, pantoprazole)
Study: 11404721
Drug: Quadruple therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple therapy (tinidazole, tetracycline, bismuth, pantoprazole)
Study: 11404721
Drug: Triple therapies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapies
Study: 11404721
Drug: Daily insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily insulin requirement in re-infected IDDM patients
Study: 3337028
Drug: Iron-fortified formula
Normalized name: INFANT FORMULA SMA IRON FORTIFIED CONC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron-fortified formula (1.6 mg Fe/100 kcal)
Study: 29282469
Drug: Esketamine 84
Normalized name: ESKETAMINE
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Esketamine 84 mg
Study: 27488675
Drug: VR-CAP (bortezomib
Approvals — FDA: no, EMA: no, PMDA: no
Description: VR-CAP (bortezomib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone)
Study: 23582626
Drug: Benazepril 40
Normalized name: benazepril 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benazepril 40 mg and Amlodipine 10 mg (B+A)
Study: 23582626
Drug: Benazepril 40
Normalized name: benazepril 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benazepril 40 mg and Hydrochlorothiazide 25 mg (B+H)
Study: 21135284
Drug: Amrubicin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amrubicin (40 mg/m²/d in a 5-minute IV infusion, days 1 through 3, every 21 days)
Study: 21135284
Drug: Topotecan (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topotecan (1.5 mg/m²/d in a 30-minute IV infusion, days 1 through 5, every 21 days)
Study: 18766378
Drug: Ethanolic DEET
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethanolic DEET solution (25% DEET)
Study: 10969352
Drug: Not prescribed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Not prescribed antiretroviral therapy
Study: 1438618
Drug: MCPP (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCPP (0.25 mg/kg, p.o.)
Study: 1438618
Drug: DMI (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMI (75 mg, i.m.)
Study: 16251172
Drug: Increasing dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increasing dosage of rh‐EPO up to 5000 U/kg/wk
Study: 16251172
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy of rh‐EPO at 1250 U/kg/wk
Study: 11912262
Drug: Angiotensin I
Normalized name: ANGIOTENSIN I
DrugBank: Angiotensin 1-7 (DB11720)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin I infusion (8 ng/kg per min) with liberal sodium intake (200 mmol sodium/d)
Study: 11912262
Drug: Angiotensin I
Normalized name: ANGIOTENSIN I
DrugBank: Angiotensin 1-7 (DB11720)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin I infusion (8 ng/kg per min) with low sodium intake (50 mmol sodium/d)
Study: 10444229
Drug: Loratadine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loratadine (10 mg per day)
Study: 10444229
Drug: Diphenhydramine (first-generation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphenhydramine (first-generation antihistamine)
Study: 7600138
Drug: Flumazenil (1
Normalized name: Flumazenil (18-F)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil (1 mg at 0.1 mg/min infusion rate)
Study: 631690
Drug: Berotec syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Berotec syrup 2.5 mg
Study: 631690
Drug: Berotec syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Berotec syrup 5.0 mg
Study: 30745346
Drug: Mobile augmented
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobile augmented reality simulator used for local anesthesia training, 2 hours weekly for four weeks.
Study: 29169472
Drug: Inhaled xenon
Normalized name: xenon
DrugBank: Xenon (DB13453)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled xenon (40% end-tidal concentration) combined with hypothermia (33°C) for 24 hours